Mangalam Drugs defaults on bank loans worth around Rs 11.54 crore

Loan classified NPACredit & Debt View source PDF Explain this filing

MANGALAM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹24.00

prior close

₹23.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.4%+0.1% vs market

Pharmaceuticals peers, median of 155sector+0.7%+0.8% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.9

10m

+2.0

15m

+2.3

30m

+1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+1.4+0.1+0.7+0.8

Next day

-0.0+1.4-1.5+0.7-0.7

+0.2+0.9-0.7+0.6-0.4

-1.5+0.3-1.8+0.0-1.5

+4.0-0.4+4.4-0.7+4.7

+9.2-0.5+9.7-0.8+10.0

+20.3+1.1+19.2-0.0+20.3

15d

+77.7-2.5+80.2-2.1+79.8

+94.8-6.1+101.0-6.2+101.0

+29.8-2.8+32.6-5.6+35.4

+21.7-14.9+36.6-13.7+35.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mangalam Drugs and Organics has defaulted on cash credit loans from Bank of Maharashtra and Bank of Baroda for over 30 days. Total overdue is Rs 1,153.82 lacs (Rs 707.05 lacs to Bank of Maharashtra and Rs 446.77 lacs to Bank of Baroda) as on 17 November 2025. The default started in October 2025. Management says they are arranging to pay the overdue amounts soon. This is a subsequent disclosure to the stock exchanges.

Likely market impact

Negative sign. The company is struggling to repay bank loans, which may hit credit rating, raise future borrowing costs, and shake shareholder confidence.